NEXMOS-넥스모스

Based On The World’s first DNA Aptamer Patent, Becoming A Global Therapeutics and Healthcare Market Leader

DNA R&D Innovator

Started business with R&D for the innovative DNA-based AD/PD medicines, and expand the business to healthcare and cosmeceutical markets
Global ingredient IPs

World’s first perfect antioxidants DNA Aptamer, Aptamin® patents rights owner (30+)
Game Changer

Go to global, and suggest new industrial standards with DNA Aptamer

2020

Aptamin®C GRAS Notification (FDA, US)

Aptamin®C additional patent registration (US, Korea)
2019

Developed Aptamin®C ingredient for skincare

Launched Aptamin®C finished cosmetic goods

Posted an study results of Aptamin®C skincare on Journal of Cosmetic Dermatology

Venture Business Certification

TIDES, Poster Presentation

AMWC, Poster Presentation

InCosmetics Global, CosmeTech

Started co-research with Kyunghee University, Chungang University, Sookmyung Women’s University
2018

Developed Aptamin®H, K, G

Publish Aptamin®C, Aptamers

Aptamin®C Korea Cosmetic Association Registration

IFSCC, Poster Presentation

IPO, Selection of an organizing company(KB securities)

Entering the global healthcare market with the start of commercializing the first DNA Aptamer in worldwide

Intellectual Property Status

2 1 7 2 7 14 8 7 PCT2 Processing
(41) Registered
(7)

Area	Applied	PCT	Registered	Total
Aptamin®	24	2	7	33
Therapeutics	12			12
Early Diagnosis	5			5
Other
Total	41	2	7	50

Build DNA R&D Center at O-song Hyper Medical Multiplex in 2021 (Total site area: 8,241.8 m²)

About Us